Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.1143 | 0.5258 | 1 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.1143 | 0.5258 | 1 |
Mycobacterium leprae | PROBABLE REPLICATIVE DNA HELICASE DNAB replicative DNA helicase | 0.2096 | 1 | 1 |
Echinococcus granulosus | Receptor type tyrosine protein phosphatase O | 0.0586 | 0.2492 | 0.3836 |
Wolbachia endosymbiont of Brugia malayi | replicative DNA helicase | 0.2096 | 1 | 1 |
Treponema pallidum | replicative DNA helicase (dnaB) | 0.2096 | 1 | 0.5 |
Mycobacterium ulcerans | replicative DNA helicase DnaB | 0.2096 | 1 | 1 |
Trypanosoma cruzi | oxidoreductase-like protein, putative | 0.0085 | 0 | 0.5 |
Leishmania major | oxidoreductase-like protein | 0.0085 | 0 | 0.5 |
Schistosoma mansoni | Replicative DNA helicase | 0.2096 | 1 | 1 |
Echinococcus granulosus | EGFP:Bcl2 fusion protein | 0.1354 | 0.6312 | 1 |
Trypanosoma brucei | oxidoreductase-like protein | 0.0085 | 0 | 0.5 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.1143 | 0.5258 | 0.5258 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.1143 | 0.5258 | 0.5258 |
Brugia malayi | Apoptosis regulator proteins, Bcl-2 family protein | 0.0108 | 0.0115 | 0.5 |
Leishmania major | pteridine reductase 1 | 0.0085 | 0 | 0.5 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.1143 | 0.5258 | 0.5 |
Mycobacterium tuberculosis | Probable replicative DNA helicase DnaB | 0.2096 | 1 | 1 |
Trichomonas vaginalis | hypothetical protein | 0.1143 | 0.5258 | 0.5 |
Loa Loa (eye worm) | twinkle helicase | 0.0599 | 0.2555 | 1 |
Echinococcus multilocularis | EGFP:Bcl2 fusion protein | 0.1354 | 0.6312 | 1 |
Onchocerca volvulus | 0.0085 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.